Home » Psychology news » Otsuka Pharmaceutical Co., Ltd. Announces Results From A Phase 2 Study Of Investigational Product OPC-34712 As Adjunctive Therapy In Adults With MDD

Otsuka Pharmaceutical Co., Ltd. Announces Results From A Phase 2 Study Of Investigational Product OPC-34712 As Adjunctive Therapy In Adults With MDD

May 16, 2011 by

Otsuka Pharmaceutical Co., Ltd. (OPC) and Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) today announced results from a Phase 2 clinical trial of OPC-34712, a novel D2 dopamine partial agonist investigational product. In a six-week, double-blind, randomized, placebo-controlled study, OPC-34712 (1.5 ± 0...

Leave a Reply

Your email address will not be published. Required fields are marked *

*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>